Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 277 No 7429 p665
2 December 2006

This article
Reprint   Photocopy

PDF 70K, Acrobat Reader

Letters

· Controlled drugs
· Pfizer products
· Counterfeit medicines
· The profession
· Statutory Committee


Letters to the Editor

Controlled drugs

Milligrams or millilitres?

From Mr N. K. K. Aling, MRPharmS

I was recently presented with a FP10MDA prescription where the right portion had been cut out and destroyed. It was for 490mg of methadone mixture 1mg/ml (sugar free). From my interpretation of the guidance provided in “Medicines, ethics and practice”, the total quantity should be expressed as 490ml rather than 490mg. This was confirmed by calling the National Pharmacy Association and the Royal Pharmaceutical Society. The Pharmacists’ Defence Association initially responded that the prescription was fine even when the total quantity was expressed in milligrams rather than in millilitres. But, after my input and further investigations on their part, I was advised that the prescription was not actually correct to dispense as such.

I then got in touch with the doctor who wrote the prescription, but he was not prepared to write the prescription with the total quantity of methadone mixture expressed in millilitres. He told me that he always writes his methadone mixture prescriptions with the total quantity to supply expressed in milligrams rather than millilitres to be safe in the event that the wrong concentration of methadone mixture has been either written on the prescription or dispensed at the pharmacy. In each of those cases, the patient would still receive the intended dose of methadone. Furthermore, he added that he had never had a pharmacist advise him to express the total quantity of methadone mixture in millilitres rather than milligrams. So, was I being difficult?

This shows that there is still some confusion over how the total quantity of schedule 2 and 3 Controlled Drugs should be expressed on prescriptions. It would be of great help if the Royal Pharmaceutical Society would issue some clear guidance on this issue. This will resolve the issue of pharmacists giving out different advice.

The National Pharmacy Association added that:

“If there was a local agreement to express the total quantity of methadone mixture to be supplied in terms of milligrams rather than millilitres for safety, it would have to be initially approved by the Home Office, otherwise the prescriptions would not be complying to CD requirements.”

I would also like to know what can be done in cases where the right portion of the prescription has been cut out and destroyed. Can we staple a blank sheet of paper to the FP10MDA prescription so that details of the items dispensed and supplied can be recorded as usual? Would that be legal and accepted by the Prescription Pricing Authority?

Nicholas Aling
London

 

CAROLE GREEN, pharmacist adviser, Fitness to Practise and Legal Affairs Directorate at the Royal Pharmaceutical Society, responds:

Regulation 15 of the Misuse of Drugs Regulations 2001, as amended, states that a prescription should specify, in the case of a prescription containing a Controlled Drug which is a preparation, either the total quantity (in both words and figures) of the preparation or the number (in both words and figures) of dosage units to be supplied; in any other case, the total quantity (in both words and figures) of the Controlled Drug to be supplied.

The Home Office, as the enforcement authority for the Misuse of Drugs Regulations, has confirmed that where a Controlled Drug is available as a dosage unit, the total quantity on a prescription should be expressed in terms of the number of dosage units, eg, the number of tablets or capsules and where the total quantity is of a liquid preparation, such as methadone mixture, it should be expressed as millilitres (ml). Therefore, the total quantity of methadone mixture as referred to in your letter should be expressed as 490ml. Further information can be obtained from the Home Office Drug Legislation and Enforcement Unit by telephoning 020 7035 0464.

In response to Mr Aling’s second question, Regulation 16, paragraphs (2) and (4) of the Misuse of Drugs Regulations 2001, as amended, state that a person supplying a Controlled Drug, other than a Controlled Drug in Schedules 4 or 5, on a prescription, shall mark the prescription with the dates on which each instalment of the drug is supplied. This is a legal requirement. The endorsements made by the pharmacist on the right side of the FP10 (MDA) of instalments supplied are to comply with this requirement.

Importantly, the right side of the prescription includes columns to record additional information that is invaluable for maintaining a complete audit trail. The additional columns allow the recording of the quantity of methadone supplied on each occasion and the supplying pharmacist’s initials for each instalment given. This information should be recorded, since it is a Code of Ethics requirement that there is a retrievable record of the pharmacist who has taken responsibility for the provision of a particular pharmacy service and that there is an accountable identifiable pharmacist for each activity.

If the right side of the prescription is missing, the Prescription Pricing Authority has confirmed that they will accept a blank piece of paper stapled to the prescription for the marking of these endorsements. However, the marking of the date of supply would still have to be made on the prescription. Pharmacists should exercise caution if considering making a supply against such a prescription. The pharmacist would have to make any necessary checks to ensure that the prescription was genuine and establish that the prescription has not been previously dispensed, before making any supplies. If the pharmacist is satisfied that the prescription is authentic, then there is no legal restriction on making a supply provided that he or she has added the required information to the prescription.

Send your letter to The Editor

Next Topic (Pfizer products)

Back to Top


©The Pharmaceutical Journal